This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papatsoris, A. G. Articles by Papavassiliou, A. G. Search for Related Content PubMed PubMed Citation Articles by Papatsoris, A. G. Articles by Papavassiliou, A. G. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Reviews

The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics

¹ Department of Biological Chemistry, Medical School, University of Athens and ² 2nd Department of Urology, Medical School, University of Athens, Sismanoglio General Hospital, Athens, Greece

Requests for reprints: Athanasios G. Papavassiliou, Department of Biological Chemistry, Medical School, University of Athens, 75 M. Asias Street, 11527 Athens, Greece. Phone: 30-210-7791207; Fax: 30-210-7791207. E-mail: papavas{at}med.uoa.gr

Prostate cancer is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths. Initially, tumor growth is androgen dependent and thus responsive to pharmacologic androgen deprivation, but there is a high rate of treatment failure because the disease evolves in an androgen-independent state. Growing evidence suggests that the Ras/mitogen-activated protein kinase (MAPK) signaling cascade represents a pivotal molecular circuitry participating directly or indirectly in prostate cancer evolution. The crucial role of the protein elements comprising this complex signal transduction network makes them potential targets for pharmacologic interference. Here, we will delineate the current knowledge regarding the involvement of the Ras/MAPK pathway in prostate carcinogenesis, spotlight ongoing research concerning the development of novel targeted agents such as the Ras/MAPK inhibitors in prostate cancer, and discuss the future perspectives of their therapeutic efficacy. [Mol Cancer Ther 2007;6(3):811–9]

This article has been cited by other articles:

				G. C. Prendergast AACR Cancer Reviews Online: A new resource for cancer researchers Cancer Reviews Online Content, April 1, 2007; 2007(1): 1 - 2. [Full Text] [PDF]